Global Hypertension Drugs research
Global Hypertension Drugs research

Hypertension Drugs Comprehensive Study by Type (Systemic Hypertension Drugs, Pulmonary Hypertension Drugs), Application (Hospital Use, Clinic Use, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), Therapeutic Class (Diuretics, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers, Others), Illness Type (Primary Hypertension, Secondary Hypertension), Medication (Monotherapy, Combination Therapy, Fixed-Dose Combinations) Players and Region - Global Market Outlook to 2026

Hypertension Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 205 Pages 166 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hypertension Drugs Market Scope?
Hypertension is defined as a condition in which the arteries in the heart have continuously increased pressure. It is also known as high blood pressure (HBP). According to the 2017 American Heart Association, high blood pressure is a blood pressure condition greater than 130 and 80 millimetres of mercury (mmHg). The measurement of blood pressure is expressed as; systolic pressure and diastolic pressure. Hypertension is a serious health condition that increases the risk of coronary artery disease and ischemic heart disease, which are the leading causes of death worldwide. Hypertension also leads to various other health problems such as heart failure, kidney dysfunction, retinal haemorrhage, and visual impairment. The main purpose of high blood pressure drugs is to lower and control high blood pressure to protect organs like the brain, heart, and kidneys.

The Hypertension Drugs market study is being classified by Type (Systemic Hypertension Drugs and Pulmonary Hypertension Drugs), by Application (Hospital Use, Clinic Use and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Research Analyst at AMA predicts that Players from United States & Japan will contribute to the maximum growth of Global Hypertension Drugs market throughout the predicted period.

Takeda Pharmaceutical Co. Ltd. (Japan), Johnson & Johnson (United States), Sun Pharmaceutical Industries (India), Bausch Health Companies Inc. (Canada), Pfizer Inc. (United States), Novartis AG (Switzerland), Daiichi Sankyo Co. Ltd. (Japan), LG Life Sciences (South Korea), Takeda Pharmaceuticals (Japan) and AstraZeneca plc (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sanofi SA (France), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Merck & Co. (United States) and Lupin Pharmaceuticals (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Hypertension Drugs market by Type, Application and Region.

On the basis of geography, the market of Hypertension Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In February 2019, after eight years of effort, Tong Ren Tang developed Yufeng Ningxin Tablet, a flagship for high blood pressure, and received marketing approval as an OTC botanical drug in the EU. Given the high standards and strict procedures of the EU, Tong Ren Tang improved accordingly with the help of experts from the Netherlands. This was the key to joining the EU market following its approval by the Drug Evaluation Board of the Netherlands.


Influencing Market Trend
  • Huge Funding In R&D and Various Initiatives by Government

Market Drivers
  • Rapid Urbanization and Globalization, Human Health Is Being Adversely Affected
  • Change In Lifestyle and Elevated Stress Levels

Opportunities
  • An Increase in Geriatric Population
  • Advancement in Technology, And Low Prices of the Drugs
  • Improved Awareness among People Regarding Hypertension and Its Available Treatment Options

Restraints
  • Availability of Alternative Therapies

Challenges
  • Relative Side Effects by the Use of Hypertension Drug


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Hypertension Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Systemic Hypertension Drugs
  • Pulmonary Hypertension Drugs
By Application
  • Hospital Use
  • Clinic Use
  • Others
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Therapeutic Class
  • Diuretics
  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensin Receptor Blockers
  • Beta-blockers
  • Vasodilators
  • Calcium Channel Blockers
  • Renin Inhibitors
  • Alpha-blockers
  • Others

By Illness Type
  • Primary Hypertension
  • Secondary Hypertension

By Medication
  • Monotherapy
  • Combination Therapy
  • Fixed-Dose Combinations

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rapid Urbanization and Globalization, Human Health Is Being Adversely Affected
      • 3.2.2. Change In Lifestyle and Elevated Stress Levels
    • 3.3. Market Challenges
      • 3.3.1. Relative Side Effects by the Use of Hypertension Drug
    • 3.4. Market Trends
      • 3.4.1. Huge Funding In R&D and Various Initiatives by Government
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hypertension Drugs, by Type, Application, Distribution Channel, Therapeutic Class, Illness Type, Medication and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hypertension Drugs (Value)
      • 5.2.1. Global Hypertension Drugs by: Type (Value)
        • 5.2.1.1. Systemic Hypertension Drugs
        • 5.2.1.2. Pulmonary Hypertension Drugs
      • 5.2.2. Global Hypertension Drugs by: Application (Value)
        • 5.2.2.1. Hospital Use
        • 5.2.2.2. Clinic Use
        • 5.2.2.3. Others
      • 5.2.3. Global Hypertension Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Hospital Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Hypertension Drugs by: Therapeutic Class (Value)
        • 5.2.4.1. Diuretics
        • 5.2.4.2. Angiotensin-Converting Enzyme Inhibitors
        • 5.2.4.3. Angiotensin Receptor Blockers
        • 5.2.4.4. Beta-blockers
        • 5.2.4.5. Vasodilators
        • 5.2.4.6. Calcium Channel Blockers
        • 5.2.4.7. Renin Inhibitors
        • 5.2.4.8. Alpha-blockers
        • 5.2.4.9. Others
      • 5.2.5. Global Hypertension Drugs by: Illness Type (Value)
        • 5.2.5.1. Primary Hypertension
        • 5.2.5.2. Secondary Hypertension
      • 5.2.6. Global Hypertension Drugs by: Medication (Value)
        • 5.2.6.1. Monotherapy
        • 5.2.6.2. Combination Therapy
        • 5.2.6.3. Fixed-Dose Combinations
      • 5.2.7. Global Hypertension Drugs Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Hypertension Drugs (Volume)
      • 5.3.1. Global Hypertension Drugs by: Type (Volume)
        • 5.3.1.1. Systemic Hypertension Drugs
        • 5.3.1.2. Pulmonary Hypertension Drugs
      • 5.3.2. Global Hypertension Drugs by: Application (Volume)
        • 5.3.2.1. Hospital Use
        • 5.3.2.2. Clinic Use
        • 5.3.2.3. Others
      • 5.3.3. Global Hypertension Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Retail Pharmacies
        • 5.3.3.2. Hospital Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Hypertension Drugs by: Therapeutic Class (Volume)
        • 5.3.4.1. Diuretics
        • 5.3.4.2. Angiotensin-Converting Enzyme Inhibitors
        • 5.3.4.3. Angiotensin Receptor Blockers
        • 5.3.4.4. Beta-blockers
        • 5.3.4.5. Vasodilators
        • 5.3.4.6. Calcium Channel Blockers
        • 5.3.4.7. Renin Inhibitors
        • 5.3.4.8. Alpha-blockers
        • 5.3.4.9. Others
      • 5.3.5. Global Hypertension Drugs by: Illness Type (Volume)
        • 5.3.5.1. Primary Hypertension
        • 5.3.5.2. Secondary Hypertension
      • 5.3.6. Global Hypertension Drugs by: Medication (Volume)
        • 5.3.6.1. Monotherapy
        • 5.3.6.2. Combination Therapy
        • 5.3.6.3. Fixed-Dose Combinations
      • 5.3.7. Global Hypertension Drugs Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Hypertension Drugs (Price)
      • 5.4.1. Global Hypertension Drugs by: Type (Price)
  • 6. Hypertension Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Co. Ltd. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health Companies Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo Co. Ltd. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LG Life Sciences (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceuticals (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hypertension Drugs Sale, by Type, Application, Distribution Channel, Therapeutic Class, Illness Type, Medication and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hypertension Drugs (Value)
      • 7.2.1. Global Hypertension Drugs by: Type (Value)
        • 7.2.1.1. Systemic Hypertension Drugs
        • 7.2.1.2. Pulmonary Hypertension Drugs
      • 7.2.2. Global Hypertension Drugs by: Application (Value)
        • 7.2.2.1. Hospital Use
        • 7.2.2.2. Clinic Use
        • 7.2.2.3. Others
      • 7.2.3. Global Hypertension Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Hospital Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Hypertension Drugs by: Therapeutic Class (Value)
        • 7.2.4.1. Diuretics
        • 7.2.4.2. Angiotensin-Converting Enzyme Inhibitors
        • 7.2.4.3. Angiotensin Receptor Blockers
        • 7.2.4.4. Beta-blockers
        • 7.2.4.5. Vasodilators
        • 7.2.4.6. Calcium Channel Blockers
        • 7.2.4.7. Renin Inhibitors
        • 7.2.4.8. Alpha-blockers
        • 7.2.4.9. Others
      • 7.2.5. Global Hypertension Drugs by: Illness Type (Value)
        • 7.2.5.1. Primary Hypertension
        • 7.2.5.2. Secondary Hypertension
      • 7.2.6. Global Hypertension Drugs by: Medication (Value)
        • 7.2.6.1. Monotherapy
        • 7.2.6.2. Combination Therapy
        • 7.2.6.3. Fixed-Dose Combinations
      • 7.2.7. Global Hypertension Drugs Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Hypertension Drugs (Volume)
      • 7.3.1. Global Hypertension Drugs by: Type (Volume)
        • 7.3.1.1. Systemic Hypertension Drugs
        • 7.3.1.2. Pulmonary Hypertension Drugs
      • 7.3.2. Global Hypertension Drugs by: Application (Volume)
        • 7.3.2.1. Hospital Use
        • 7.3.2.2. Clinic Use
        • 7.3.2.3. Others
      • 7.3.3. Global Hypertension Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Retail Pharmacies
        • 7.3.3.2. Hospital Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Hypertension Drugs by: Therapeutic Class (Volume)
        • 7.3.4.1. Diuretics
        • 7.3.4.2. Angiotensin-Converting Enzyme Inhibitors
        • 7.3.4.3. Angiotensin Receptor Blockers
        • 7.3.4.4. Beta-blockers
        • 7.3.4.5. Vasodilators
        • 7.3.4.6. Calcium Channel Blockers
        • 7.3.4.7. Renin Inhibitors
        • 7.3.4.8. Alpha-blockers
        • 7.3.4.9. Others
      • 7.3.5. Global Hypertension Drugs by: Illness Type (Volume)
        • 7.3.5.1. Primary Hypertension
        • 7.3.5.2. Secondary Hypertension
      • 7.3.6. Global Hypertension Drugs by: Medication (Volume)
        • 7.3.6.1. Monotherapy
        • 7.3.6.2. Combination Therapy
        • 7.3.6.3. Fixed-Dose Combinations
      • 7.3.7. Global Hypertension Drugs Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Hypertension Drugs (Price)
      • 7.4.1. Global Hypertension Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hypertension Drugs: by Type(USD Million)
  • Table 2. Hypertension Drugs Systemic Hypertension Drugs , by Region USD Million (2015-2020)
  • Table 3. Hypertension Drugs Pulmonary Hypertension Drugs , by Region USD Million (2015-2020)
  • Table 4. Hypertension Drugs: by Application(USD Million)
  • Table 5. Hypertension Drugs Hospital Use , by Region USD Million (2015-2020)
  • Table 6. Hypertension Drugs Clinic Use , by Region USD Million (2015-2020)
  • Table 7. Hypertension Drugs Others , by Region USD Million (2015-2020)
  • Table 8. Hypertension Drugs: by Distribution Channel(USD Million)
  • Table 9. Hypertension Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Hypertension Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Hypertension Drugs Online Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Hypertension Drugs: by Therapeutic Class(USD Million)
  • Table 13. Hypertension Drugs Diuretics , by Region USD Million (2015-2020)
  • Table 14. Hypertension Drugs Angiotensin-Converting Enzyme Inhibitors , by Region USD Million (2015-2020)
  • Table 15. Hypertension Drugs Angiotensin Receptor Blockers , by Region USD Million (2015-2020)
  • Table 16. Hypertension Drugs Beta-blockers , by Region USD Million (2015-2020)
  • Table 17. Hypertension Drugs Vasodilators , by Region USD Million (2015-2020)
  • Table 18. Hypertension Drugs Calcium Channel Blockers , by Region USD Million (2015-2020)
  • Table 19. Hypertension Drugs Renin Inhibitors , by Region USD Million (2015-2020)
  • Table 20. Hypertension Drugs Alpha-blockers , by Region USD Million (2015-2020)
  • Table 21. Hypertension Drugs Others , by Region USD Million (2015-2020)
  • Table 22. Hypertension Drugs: by Illness Type(USD Million)
  • Table 23. Hypertension Drugs Primary Hypertension , by Region USD Million (2015-2020)
  • Table 24. Hypertension Drugs Secondary Hypertension , by Region USD Million (2015-2020)
  • Table 25. Hypertension Drugs: by Medication(USD Million)
  • Table 26. Hypertension Drugs Monotherapy , by Region USD Million (2015-2020)
  • Table 27. Hypertension Drugs Combination Therapy , by Region USD Million (2015-2020)
  • Table 28. Hypertension Drugs Fixed-Dose Combinations , by Region USD Million (2015-2020)
  • Table 29. South America Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 30. South America Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 31. South America Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 32. South America Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 33. South America Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 34. South America Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 35. South America Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 36. Brazil Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 37. Brazil Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 38. Brazil Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 39. Brazil Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 40. Brazil Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 41. Brazil Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 42. Argentina Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 43. Argentina Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 44. Argentina Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 45. Argentina Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 46. Argentina Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 47. Argentina Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 48. Rest of South America Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 49. Rest of South America Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 50. Rest of South America Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of South America Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 52. Rest of South America Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 53. Rest of South America Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 54. Asia Pacific Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 55. Asia Pacific Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 56. Asia Pacific Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 57. Asia Pacific Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. Asia Pacific Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 59. Asia Pacific Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 60. Asia Pacific Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 61. China Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 62. China Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 63. China Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 64. China Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 65. China Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 66. China Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 67. Japan Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 68. Japan Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 69. Japan Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 70. Japan Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 71. Japan Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 72. Japan Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 73. India Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 74. India Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 75. India Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. India Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 77. India Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 78. India Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 79. South Korea Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 80. South Korea Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 81. South Korea Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 82. South Korea Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 83. South Korea Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 84. South Korea Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 85. Taiwan Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 86. Taiwan Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 87. Taiwan Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 88. Taiwan Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 89. Taiwan Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 90. Taiwan Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 91. Australia Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 92. Australia Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 93. Australia Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 94. Australia Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 95. Australia Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 96. Australia Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 103. Europe Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 104. Europe Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 105. Europe Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 106. Europe Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 107. Europe Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 108. Europe Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 109. Europe Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 110. Germany Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 111. Germany Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 112. Germany Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 113. Germany Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 114. Germany Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 115. Germany Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 116. France Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 117. France Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 118. France Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 119. France Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 120. France Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 121. France Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 122. Italy Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 123. Italy Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 124. Italy Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 125. Italy Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 126. Italy Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 127. Italy Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 128. United Kingdom Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 129. United Kingdom Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 130. United Kingdom Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 131. United Kingdom Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 132. United Kingdom Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 133. United Kingdom Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 134. Netherlands Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 135. Netherlands Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 136. Netherlands Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 137. Netherlands Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 138. Netherlands Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 139. Netherlands Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 140. Rest of Europe Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 141. Rest of Europe Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 142. Rest of Europe Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 143. Rest of Europe Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 144. Rest of Europe Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 145. Rest of Europe Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 146. MEA Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 147. MEA Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 148. MEA Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 149. MEA Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 150. MEA Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 151. MEA Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 152. MEA Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 153. Middle East Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 154. Middle East Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 155. Middle East Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 156. Middle East Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 157. Middle East Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 158. Middle East Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 159. Africa Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 160. Africa Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 161. Africa Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 162. Africa Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 163. Africa Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 164. Africa Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 165. North America Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 166. North America Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 167. North America Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 168. North America Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 169. North America Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 170. North America Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 171. North America Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 172. United States Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 173. United States Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 174. United States Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 175. United States Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 176. United States Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 177. United States Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 178. Canada Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 179. Canada Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 180. Canada Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 181. Canada Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 182. Canada Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 183. Canada Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 184. Mexico Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 185. Mexico Hypertension Drugs, by Application USD Million (2015-2020)
  • Table 186. Mexico Hypertension Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 187. Mexico Hypertension Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 188. Mexico Hypertension Drugs, by Illness Type USD Million (2015-2020)
  • Table 189. Mexico Hypertension Drugs, by Medication USD Million (2015-2020)
  • Table 190. Hypertension Drugs Sales: by Type(K Tons)
  • Table 191. Hypertension Drugs Sales Systemic Hypertension Drugs , by Region K Tons (2015-2020)
  • Table 192. Hypertension Drugs Sales Pulmonary Hypertension Drugs , by Region K Tons (2015-2020)
  • Table 193. Hypertension Drugs Sales: by Application(K Tons)
  • Table 194. Hypertension Drugs Sales Hospital Use , by Region K Tons (2015-2020)
  • Table 195. Hypertension Drugs Sales Clinic Use , by Region K Tons (2015-2020)
  • Table 196. Hypertension Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 197. Hypertension Drugs Sales: by Distribution Channel(K Tons)
  • Table 198. Hypertension Drugs Sales Retail Pharmacies , by Region K Tons (2015-2020)
  • Table 199. Hypertension Drugs Sales Hospital Pharmacies , by Region K Tons (2015-2020)
  • Table 200. Hypertension Drugs Sales Online Pharmacies , by Region K Tons (2015-2020)
  • Table 201. Hypertension Drugs Sales: by Therapeutic Class(K Tons)
  • Table 202. Hypertension Drugs Sales Diuretics , by Region K Tons (2015-2020)
  • Table 203. Hypertension Drugs Sales Angiotensin-Converting Enzyme Inhibitors , by Region K Tons (2015-2020)
  • Table 204. Hypertension Drugs Sales Angiotensin Receptor Blockers , by Region K Tons (2015-2020)
  • Table 205. Hypertension Drugs Sales Beta-blockers , by Region K Tons (2015-2020)
  • Table 206. Hypertension Drugs Sales Vasodilators , by Region K Tons (2015-2020)
  • Table 207. Hypertension Drugs Sales Calcium Channel Blockers , by Region K Tons (2015-2020)
  • Table 208. Hypertension Drugs Sales Renin Inhibitors , by Region K Tons (2015-2020)
  • Table 209. Hypertension Drugs Sales Alpha-blockers , by Region K Tons (2015-2020)
  • Table 210. Hypertension Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 211. Hypertension Drugs Sales: by Illness Type(K Tons)
  • Table 212. Hypertension Drugs Sales Primary Hypertension , by Region K Tons (2015-2020)
  • Table 213. Hypertension Drugs Sales Secondary Hypertension , by Region K Tons (2015-2020)
  • Table 214. Hypertension Drugs Sales: by Medication(K Tons)
  • Table 215. Hypertension Drugs Sales Monotherapy , by Region K Tons (2015-2020)
  • Table 216. Hypertension Drugs Sales Combination Therapy , by Region K Tons (2015-2020)
  • Table 217. Hypertension Drugs Sales Fixed-Dose Combinations , by Region K Tons (2015-2020)
  • Table 218. South America Hypertension Drugs Sales, by Country K Tons (2015-2020)
  • Table 219. South America Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 220. South America Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 221. South America Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 222. South America Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 223. South America Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 224. South America Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 225. Brazil Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 226. Brazil Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 227. Brazil Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. Brazil Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 229. Brazil Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 230. Brazil Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 231. Argentina Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 232. Argentina Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 233. Argentina Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 234. Argentina Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 235. Argentina Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 236. Argentina Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 237. Rest of South America Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 238. Rest of South America Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 239. Rest of South America Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 240. Rest of South America Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 241. Rest of South America Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 242. Rest of South America Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 243. Asia Pacific Hypertension Drugs Sales, by Country K Tons (2015-2020)
  • Table 244. Asia Pacific Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 245. Asia Pacific Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 246. Asia Pacific Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 247. Asia Pacific Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 248. Asia Pacific Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 249. Asia Pacific Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 250. China Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 251. China Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 252. China Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 253. China Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 254. China Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 255. China Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 256. Japan Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 257. Japan Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 258. Japan Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 259. Japan Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 260. Japan Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 261. Japan Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 262. India Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 263. India Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 264. India Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 265. India Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 266. India Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 267. India Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 268. South Korea Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 269. South Korea Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 270. South Korea Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 271. South Korea Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 272. South Korea Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 273. South Korea Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 274. Taiwan Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 275. Taiwan Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 276. Taiwan Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 277. Taiwan Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 278. Taiwan Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 279. Taiwan Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 280. Australia Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 281. Australia Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 282. Australia Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 283. Australia Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 284. Australia Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 285. Australia Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 286. Rest of Asia-Pacific Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 287. Rest of Asia-Pacific Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 288. Rest of Asia-Pacific Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 289. Rest of Asia-Pacific Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 290. Rest of Asia-Pacific Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 291. Rest of Asia-Pacific Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 292. Europe Hypertension Drugs Sales, by Country K Tons (2015-2020)
  • Table 293. Europe Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 294. Europe Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 295. Europe Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 296. Europe Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 297. Europe Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 298. Europe Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 299. Germany Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 300. Germany Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 301. Germany Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 302. Germany Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 303. Germany Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 304. Germany Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 305. France Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 306. France Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 307. France Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 308. France Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 309. France Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 310. France Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 311. Italy Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 312. Italy Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 313. Italy Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 314. Italy Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 315. Italy Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 316. Italy Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 317. United Kingdom Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 318. United Kingdom Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 319. United Kingdom Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 320. United Kingdom Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 321. United Kingdom Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 322. United Kingdom Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 323. Netherlands Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 324. Netherlands Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 325. Netherlands Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 326. Netherlands Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 327. Netherlands Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 328. Netherlands Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 329. Rest of Europe Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 330. Rest of Europe Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 331. Rest of Europe Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 332. Rest of Europe Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 333. Rest of Europe Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 334. Rest of Europe Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 335. MEA Hypertension Drugs Sales, by Country K Tons (2015-2020)
  • Table 336. MEA Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 337. MEA Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 338. MEA Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 339. MEA Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 340. MEA Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 341. MEA Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 342. Middle East Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 343. Middle East Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 344. Middle East Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 345. Middle East Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 346. Middle East Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 347. Middle East Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 348. Africa Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 349. Africa Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 350. Africa Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 351. Africa Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 352. Africa Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 353. Africa Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 354. North America Hypertension Drugs Sales, by Country K Tons (2015-2020)
  • Table 355. North America Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 356. North America Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 357. North America Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 358. North America Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 359. North America Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 360. North America Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 361. United States Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 362. United States Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 363. United States Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 364. United States Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 365. United States Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 366. United States Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 367. Canada Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 368. Canada Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 369. Canada Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 370. Canada Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 371. Canada Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 372. Canada Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 373. Mexico Hypertension Drugs Sales, by Type K Tons (2015-2020)
  • Table 374. Mexico Hypertension Drugs Sales, by Application K Tons (2015-2020)
  • Table 375. Mexico Hypertension Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 376. Mexico Hypertension Drugs Sales, by Therapeutic Class K Tons (2015-2020)
  • Table 377. Mexico Hypertension Drugs Sales, by Illness Type K Tons (2015-2020)
  • Table 378. Mexico Hypertension Drugs Sales, by Medication K Tons (2015-2020)
  • Table 379. Hypertension Drugs: by Type(USD/Units)
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Company Basic Information, Sales Area and Its Competitors
  • Table 383. Company Basic Information, Sales Area and Its Competitors
  • Table 384. Company Basic Information, Sales Area and Its Competitors
  • Table 385. Company Basic Information, Sales Area and Its Competitors
  • Table 386. Company Basic Information, Sales Area and Its Competitors
  • Table 387. Company Basic Information, Sales Area and Its Competitors
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. Company Basic Information, Sales Area and Its Competitors
  • Table 390. Hypertension Drugs: by Type(USD Million)
  • Table 391. Hypertension Drugs Systemic Hypertension Drugs , by Region USD Million (2021-2026)
  • Table 392. Hypertension Drugs Pulmonary Hypertension Drugs , by Region USD Million (2021-2026)
  • Table 393. Hypertension Drugs: by Application(USD Million)
  • Table 394. Hypertension Drugs Hospital Use , by Region USD Million (2021-2026)
  • Table 395. Hypertension Drugs Clinic Use , by Region USD Million (2021-2026)
  • Table 396. Hypertension Drugs Others , by Region USD Million (2021-2026)
  • Table 397. Hypertension Drugs: by Distribution Channel(USD Million)
  • Table 398. Hypertension Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 399. Hypertension Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 400. Hypertension Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 401. Hypertension Drugs: by Therapeutic Class(USD Million)
  • Table 402. Hypertension Drugs Diuretics , by Region USD Million (2021-2026)
  • Table 403. Hypertension Drugs Angiotensin-Converting Enzyme Inhibitors , by Region USD Million (2021-2026)
  • Table 404. Hypertension Drugs Angiotensin Receptor Blockers , by Region USD Million (2021-2026)
  • Table 405. Hypertension Drugs Beta-blockers , by Region USD Million (2021-2026)
  • Table 406. Hypertension Drugs Vasodilators , by Region USD Million (2021-2026)
  • Table 407. Hypertension Drugs Calcium Channel Blockers , by Region USD Million (2021-2026)
  • Table 408. Hypertension Drugs Renin Inhibitors , by Region USD Million (2021-2026)
  • Table 409. Hypertension Drugs Alpha-blockers , by Region USD Million (2021-2026)
  • Table 410. Hypertension Drugs Others , by Region USD Million (2021-2026)
  • Table 411. Hypertension Drugs: by Illness Type(USD Million)
  • Table 412. Hypertension Drugs Primary Hypertension , by Region USD Million (2021-2026)
  • Table 413. Hypertension Drugs Secondary Hypertension , by Region USD Million (2021-2026)
  • Table 414. Hypertension Drugs: by Medication(USD Million)
  • Table 415. Hypertension Drugs Monotherapy , by Region USD Million (2021-2026)
  • Table 416. Hypertension Drugs Combination Therapy , by Region USD Million (2021-2026)
  • Table 417. Hypertension Drugs Fixed-Dose Combinations , by Region USD Million (2021-2026)
  • Table 418. South America Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 419. South America Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 420. South America Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 421. South America Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 422. South America Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 423. South America Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 424. South America Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 425. Brazil Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 426. Brazil Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 427. Brazil Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 428. Brazil Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 429. Brazil Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 430. Brazil Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 431. Argentina Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 432. Argentina Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 433. Argentina Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 434. Argentina Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 435. Argentina Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 436. Argentina Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 437. Rest of South America Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 438. Rest of South America Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 439. Rest of South America Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 440. Rest of South America Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 441. Rest of South America Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 442. Rest of South America Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 443. Asia Pacific Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 444. Asia Pacific Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 445. Asia Pacific Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 446. Asia Pacific Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 447. Asia Pacific Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 448. Asia Pacific Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 449. Asia Pacific Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 450. China Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 451. China Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 452. China Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 453. China Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 454. China Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 455. China Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 456. Japan Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 457. Japan Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 458. Japan Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 459. Japan Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 460. Japan Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 461. Japan Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 462. India Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 463. India Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 464. India Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 465. India Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 466. India Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 467. India Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 468. South Korea Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 469. South Korea Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 470. South Korea Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 471. South Korea Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 472. South Korea Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 473. South Korea Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 474. Taiwan Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 475. Taiwan Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 476. Taiwan Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 477. Taiwan Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 478. Taiwan Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 479. Taiwan Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 480. Australia Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 481. Australia Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 482. Australia Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 483. Australia Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 484. Australia Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 485. Australia Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 486. Rest of Asia-Pacific Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 487. Rest of Asia-Pacific Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 488. Rest of Asia-Pacific Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 489. Rest of Asia-Pacific Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 490. Rest of Asia-Pacific Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 491. Rest of Asia-Pacific Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 492. Europe Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 493. Europe Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 494. Europe Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 495. Europe Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 496. Europe Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 497. Europe Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 498. Europe Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 499. Germany Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 500. Germany Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 501. Germany Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 502. Germany Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 503. Germany Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 504. Germany Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 505. France Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 506. France Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 507. France Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 508. France Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 509. France Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 510. France Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 511. Italy Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 512. Italy Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 513. Italy Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 514. Italy Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 515. Italy Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 516. Italy Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 517. United Kingdom Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 518. United Kingdom Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 519. United Kingdom Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 520. United Kingdom Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 521. United Kingdom Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 522. United Kingdom Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 523. Netherlands Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 524. Netherlands Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 525. Netherlands Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 526. Netherlands Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 527. Netherlands Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 528. Netherlands Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 529. Rest of Europe Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 530. Rest of Europe Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 531. Rest of Europe Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 532. Rest of Europe Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 533. Rest of Europe Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 534. Rest of Europe Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 535. MEA Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 536. MEA Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 537. MEA Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 538. MEA Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 539. MEA Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 540. MEA Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 541. MEA Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 542. Middle East Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 543. Middle East Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 544. Middle East Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 545. Middle East Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 546. Middle East Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 547. Middle East Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 548. Africa Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 549. Africa Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 550. Africa Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 551. Africa Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 552. Africa Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 553. Africa Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 554. North America Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 555. North America Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 556. North America Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 557. North America Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 558. North America Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 559. North America Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 560. North America Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 561. United States Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 562. United States Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 563. United States Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 564. United States Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 565. United States Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 566. United States Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 567. Canada Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 568. Canada Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 569. Canada Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 570. Canada Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 571. Canada Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 572. Canada Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 573. Mexico Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 574. Mexico Hypertension Drugs, by Application USD Million (2021-2026)
  • Table 575. Mexico Hypertension Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 576. Mexico Hypertension Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 577. Mexico Hypertension Drugs, by Illness Type USD Million (2021-2026)
  • Table 578. Mexico Hypertension Drugs, by Medication USD Million (2021-2026)
  • Table 579. Hypertension Drugs Sales: by Type(K Tons)
  • Table 580. Hypertension Drugs Sales Systemic Hypertension Drugs , by Region K Tons (2021-2026)
  • Table 581. Hypertension Drugs Sales Pulmonary Hypertension Drugs , by Region K Tons (2021-2026)
  • Table 582. Hypertension Drugs Sales: by Application(K Tons)
  • Table 583. Hypertension Drugs Sales Hospital Use , by Region K Tons (2021-2026)
  • Table 584. Hypertension Drugs Sales Clinic Use , by Region K Tons (2021-2026)
  • Table 585. Hypertension Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 586. Hypertension Drugs Sales: by Distribution Channel(K Tons)
  • Table 587. Hypertension Drugs Sales Retail Pharmacies , by Region K Tons (2021-2026)
  • Table 588. Hypertension Drugs Sales Hospital Pharmacies , by Region K Tons (2021-2026)
  • Table 589. Hypertension Drugs Sales Online Pharmacies , by Region K Tons (2021-2026)
  • Table 590. Hypertension Drugs Sales: by Therapeutic Class(K Tons)
  • Table 591. Hypertension Drugs Sales Diuretics , by Region K Tons (2021-2026)
  • Table 592. Hypertension Drugs Sales Angiotensin-Converting Enzyme Inhibitors , by Region K Tons (2021-2026)
  • Table 593. Hypertension Drugs Sales Angiotensin Receptor Blockers , by Region K Tons (2021-2026)
  • Table 594. Hypertension Drugs Sales Beta-blockers , by Region K Tons (2021-2026)
  • Table 595. Hypertension Drugs Sales Vasodilators , by Region K Tons (2021-2026)
  • Table 596. Hypertension Drugs Sales Calcium Channel Blockers , by Region K Tons (2021-2026)
  • Table 597. Hypertension Drugs Sales Renin Inhibitors , by Region K Tons (2021-2026)
  • Table 598. Hypertension Drugs Sales Alpha-blockers , by Region K Tons (2021-2026)
  • Table 599. Hypertension Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 600. Hypertension Drugs Sales: by Illness Type(K Tons)
  • Table 601. Hypertension Drugs Sales Primary Hypertension , by Region K Tons (2021-2026)
  • Table 602. Hypertension Drugs Sales Secondary Hypertension , by Region K Tons (2021-2026)
  • Table 603. Hypertension Drugs Sales: by Medication(K Tons)
  • Table 604. Hypertension Drugs Sales Monotherapy , by Region K Tons (2021-2026)
  • Table 605. Hypertension Drugs Sales Combination Therapy , by Region K Tons (2021-2026)
  • Table 606. Hypertension Drugs Sales Fixed-Dose Combinations , by Region K Tons (2021-2026)
  • Table 607. South America Hypertension Drugs Sales, by Country K Tons (2021-2026)
  • Table 608. South America Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 609. South America Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 610. South America Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 611. South America Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 612. South America Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 613. South America Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 614. Brazil Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 615. Brazil Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 616. Brazil Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 617. Brazil Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 618. Brazil Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 619. Brazil Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 620. Argentina Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 621. Argentina Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 622. Argentina Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 623. Argentina Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 624. Argentina Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 625. Argentina Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 626. Rest of South America Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 627. Rest of South America Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 628. Rest of South America Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 629. Rest of South America Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 630. Rest of South America Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 631. Rest of South America Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 632. Asia Pacific Hypertension Drugs Sales, by Country K Tons (2021-2026)
  • Table 633. Asia Pacific Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 634. Asia Pacific Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 635. Asia Pacific Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 636. Asia Pacific Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 637. Asia Pacific Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 638. Asia Pacific Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 639. China Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 640. China Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 641. China Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 642. China Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 643. China Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 644. China Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 645. Japan Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 646. Japan Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 647. Japan Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 648. Japan Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 649. Japan Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 650. Japan Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 651. India Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 652. India Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 653. India Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 654. India Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 655. India Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 656. India Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 657. South Korea Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 658. South Korea Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 659. South Korea Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 660. South Korea Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 661. South Korea Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 662. South Korea Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 663. Taiwan Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 664. Taiwan Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 665. Taiwan Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 666. Taiwan Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 667. Taiwan Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 668. Taiwan Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 669. Australia Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 670. Australia Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 671. Australia Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 672. Australia Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 673. Australia Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 674. Australia Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 675. Rest of Asia-Pacific Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 676. Rest of Asia-Pacific Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 677. Rest of Asia-Pacific Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 678. Rest of Asia-Pacific Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 679. Rest of Asia-Pacific Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 680. Rest of Asia-Pacific Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 681. Europe Hypertension Drugs Sales, by Country K Tons (2021-2026)
  • Table 682. Europe Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 683. Europe Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 684. Europe Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 685. Europe Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 686. Europe Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 687. Europe Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 688. Germany Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 689. Germany Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 690. Germany Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 691. Germany Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 692. Germany Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 693. Germany Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 694. France Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 695. France Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 696. France Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 697. France Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 698. France Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 699. France Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 700. Italy Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 701. Italy Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 702. Italy Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 703. Italy Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 704. Italy Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 705. Italy Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 706. United Kingdom Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 707. United Kingdom Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 708. United Kingdom Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 709. United Kingdom Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 710. United Kingdom Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 711. United Kingdom Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 712. Netherlands Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 713. Netherlands Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 714. Netherlands Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 715. Netherlands Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 716. Netherlands Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 717. Netherlands Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 718. Rest of Europe Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 719. Rest of Europe Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 720. Rest of Europe Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 721. Rest of Europe Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 722. Rest of Europe Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 723. Rest of Europe Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 724. MEA Hypertension Drugs Sales, by Country K Tons (2021-2026)
  • Table 725. MEA Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 726. MEA Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 727. MEA Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 728. MEA Hypertension Drugs Sales, by Therapeutic Class K Tons (2021-2026)
  • Table 729. MEA Hypertension Drugs Sales, by Illness Type K Tons (2021-2026)
  • Table 730. MEA Hypertension Drugs Sales, by Medication K Tons (2021-2026)
  • Table 731. Middle East Hypertension Drugs Sales, by Type K Tons (2021-2026)
  • Table 732. Middle East Hypertension Drugs Sales, by Application K Tons (2021-2026)
  • Table 733. Middle East Hypertension Drugs Sales, by Distribution Channel K Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hypertension Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Hypertension Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Hypertension Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Hypertension Drugs: by Therapeutic Class USD Million (2015-2020)
  • Figure 8. Global Hypertension Drugs: by Illness Type USD Million (2015-2020)
  • Figure 9. Global Hypertension Drugs: by Medication USD Million (2015-2020)
  • Figure 10. South America Hypertension Drugs Share (%), by Country
  • Figure 11. Asia Pacific Hypertension Drugs Share (%), by Country
  • Figure 12. Europe Hypertension Drugs Share (%), by Country
  • Figure 13. MEA Hypertension Drugs Share (%), by Country
  • Figure 14. North America Hypertension Drugs Share (%), by Country
  • Figure 15. Global Hypertension Drugs: by Type K Tons (2015-2020)
  • Figure 16. Global Hypertension Drugs: by Application K Tons (2015-2020)
  • Figure 17. Global Hypertension Drugs: by Distribution Channel K Tons (2015-2020)
  • Figure 18. Global Hypertension Drugs: by Therapeutic Class K Tons (2015-2020)
  • Figure 19. Global Hypertension Drugs: by Illness Type K Tons (2015-2020)
  • Figure 20. Global Hypertension Drugs: by Medication K Tons (2015-2020)
  • Figure 21. South America Hypertension Drugs Share (%), by Country
  • Figure 22. Asia Pacific Hypertension Drugs Share (%), by Country
  • Figure 23. Europe Hypertension Drugs Share (%), by Country
  • Figure 24. MEA Hypertension Drugs Share (%), by Country
  • Figure 25. North America Hypertension Drugs Share (%), by Country
  • Figure 26. Global Hypertension Drugs: by Type USD/Units (2015-2020)
  • Figure 27. Global Hypertension Drugs share by Players 2020 (%)
  • Figure 28. Global Hypertension Drugs share by Players (Top 3) 2020(%)
  • Figure 29. Global Hypertension Drugs share by Players (Top 5) 2020(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. Takeda Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Takeda Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2020
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 35. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 36. Sun Pharmaceutical Industries (India) Revenue: by Geography 2020
  • Figure 37. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 38. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 39. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 43. Daiichi Sankyo Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Daiichi Sankyo Co. Ltd. (Japan) Revenue: by Geography 2020
  • Figure 45. LG Life Sciences (South Korea) Revenue, Net Income and Gross profit
  • Figure 46. LG Life Sciences (South Korea) Revenue: by Geography 2020
  • Figure 47. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2020
  • Figure 49. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 50. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 51. Global Hypertension Drugs: by Type USD Million (2021-2026)
  • Figure 52. Global Hypertension Drugs: by Application USD Million (2021-2026)
  • Figure 53. Global Hypertension Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 54. Global Hypertension Drugs: by Therapeutic Class USD Million (2021-2026)
  • Figure 55. Global Hypertension Drugs: by Illness Type USD Million (2021-2026)
  • Figure 56. Global Hypertension Drugs: by Medication USD Million (2021-2026)
  • Figure 57. South America Hypertension Drugs Share (%), by Country
  • Figure 58. Asia Pacific Hypertension Drugs Share (%), by Country
  • Figure 59. Europe Hypertension Drugs Share (%), by Country
  • Figure 60. MEA Hypertension Drugs Share (%), by Country
  • Figure 61. North America Hypertension Drugs Share (%), by Country
  • Figure 62. Global Hypertension Drugs: by Type K Tons (2021-2026)
  • Figure 63. Global Hypertension Drugs: by Application K Tons (2021-2026)
  • Figure 64. Global Hypertension Drugs: by Distribution Channel K Tons (2021-2026)
  • Figure 65. Global Hypertension Drugs: by Therapeutic Class K Tons (2021-2026)
  • Figure 66. Global Hypertension Drugs: by Illness Type K Tons (2021-2026)
  • Figure 67. Global Hypertension Drugs: by Medication K Tons (2021-2026)
  • Figure 68. South America Hypertension Drugs Share (%), by Country
  • Figure 69. Asia Pacific Hypertension Drugs Share (%), by Country
  • Figure 70. Europe Hypertension Drugs Share (%), by Country
  • Figure 71. MEA Hypertension Drugs Share (%), by Country
  • Figure 72. North America Hypertension Drugs Share (%), by Country
  • Figure 73. Global Hypertension Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Takeda Pharmaceutical Co. Ltd. (Japan)
  • Johnson & Johnson (United States)
  • Sun Pharmaceutical Industries (India)
  • Bausch Health Companies Inc. (Canada)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Daiichi Sankyo Co. Ltd. (Japan)
  • LG Life Sciences (South Korea)
  • Takeda Pharmaceuticals (Japan)
  • AstraZeneca plc (United Kingdom)
Additional players considered in the study are as follows:
Sanofi SA (France) , Bayer AG (Germany) , Boehringer Ingelheim GmbH (Germany) , Merck & Co. (United States) , Lupin Pharmaceuticals (India) ,
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Biotin Comprehensive Study by Type (Tablets, Capsules ( Soft gel capsules, Hard gel capsules), Lotions, Serums, Others), Application (Food, Pharma & Cosmetics, Animal Feed), Biotin Type (1% D-Biotin ...
Biotin Comprehensive Study by Type (Tablets, Capsules ( Soft gel capsules, Hard gel capsules), Lotions, Serums, Others), Application (Food, Pharma & Cosmetics, Animal Feed), Biotin Type (1% D-Biotin ...
$ 3800
Anesthesia Drug Comprehensive Study by Type (General Anesthesia Drugs (Propofol, Sevoflurane, Desflurane, Dexmedetomidine, Remifentanil, Midazolam, Other General Anesthesia Drugs), Local Anesthesia D...
Anesthesia Drug Comprehensive Study by Type (General Anesthesia Drugs (Propofol, Sevoflurane, Desflurane, Dexmedetomidine, Remifentanil, Midazolam, Other General Anesthesia Drugs), Local Anesthesia D...
$ 3800
Celiac Disease Drug Comprehensive Study by Application (Hospitals, Clinics, Other), Distribution Channel (Over the Counter (OTC), Prescribed Medicine), Treatment Type (First-Line Treatment, Second-Li...
Celiac Disease Drug Comprehensive Study by Application (Hospitals, Clinics, Other), Distribution Channel (Over the Counter (OTC), Prescribed Medicine), Treatment Type (First-Line Treatment, Second-Li...
$ 3800
H1N1 (swine flu) Vaccination Comprehensive Study by Treatment type (Influenza, Meningococcal, Cervical cancer, Pneumococcal, Hepatitis, Measles, Mumps, Rubella), End user (Hospital, Clinics) Players ...
H1N1 (swine flu) Vaccination Comprehensive Study by Treatment type (Influenza, Meningococcal, Cervical cancer, Pneumococcal, Hepatitis, Measles, Mumps, Rubella), End user (Hospital, Clinics) Players ...
$ 3800
Protein Expression Comprehensive Study by Application (Therapeutic, Research, Industrial), Systems Type (Prokaryotic Expression Systems {Escherichia coli (E. coli) Systems and Other Systems}, Mammali...
Protein Expression Comprehensive Study by Application (Therapeutic, Research, Industrial), Systems Type (Prokaryotic Expression Systems {Escherichia coli (E. coli) Systems and Other Systems}, Mammali...
$ 3800
Regenerative Medicine Comprehensive Study by Type (Cell-Based, Acellular), Application (Cardiovascular, Oncology, Dermatology, Wound Healing, Neurology, Others), Technology (Stem Cell Therapy, Platel...
Regenerative Medicine Comprehensive Study by Type (Cell-Based, Acellular), Application (Cardiovascular, Oncology, Dermatology, Wound Healing, Neurology, Others), Technology (Stem Cell Therapy, Platel...
$ 3800